This handout is for nstemi in active-cancer patient (cardio-oncology bleeding-risk balance). Your care team identified this based on: nste-acs pattern in patient with active malignancy (currently on chemo/radiation/immunotherapy/targeted therapy or within 6 mo of completion).
Other reasons your team may use this plan: hstn rise in cancer patient with platelets <100k — high-bleeding-risk antithrombotic decision; chest pain in cancer patient with anemia / infection / dehydration / hypoxemia / severe pain — type-2 nstemi candidate (4th udmi pmid 30153967); dynamic ecg changes in patient on cardio-toxic chemotherapy (5-fu, capecitabine) — vasospasm-mediated acs suspicion.
Take these medications exactly as prescribed. Do not stop or change a dose without talking to your provider.
| Medication | Starting dose | How | When | What it does |
|---|---|---|---|---|
| aspirin | 162–325 mg load if not on ASA → 81 mg daily | PO | load + 81 mg daily long-term | ACC/AHA 2025 Class I; continued in nearly all cancer NSTEMI patients with platelets >50K |
| clopidogrel | 300–600 mg load → 75 mg daily | PO | daily × 3–6 mo per high-bleeding-risk modification | Preferred over ticagrelor/prasugrel in cancer because of better bleeding profile + drug interaction tolerability; 3–6 mo DAPT per MASTER DAPT PMID 34516952 + ESC cardio-onc 2022 §6.4 |
| ticagrelor | 180 mg load → 90 mg BID | PO | BID × 3–6 mo per high-bleeding-risk modification | PLATO PMID 19717846; superior to clopidogrel for ischemic events but higher bleeding; AVOID if active intracranial mass or recent bleed; can de-escalate to ticagrelor monotherapy after 3 mo per TWILIGHT PMID 31475798 |
| unfractionated_heparin | 60 U/kg bolus (max 4000) → 12 U/kg/h infusion | IV | continuous, aPTT 1.5–2× control × 24h post-PCI | ACC/AHA 2025 Class I parenteral AC; preferred over LMWH in cancer due to reversibility + renal-friendly + no accumulation |
| atorvastatin | 80 mg | PO | daily | PROVE-IT PMID 15007110; multiple cardio-oncology registries show benefit + low toxicity in cancer; reduce to 40 mg if hepatic dysfunction |
| carvedilol | 3.125 mg BID titrate to 25 mg BID | PO | BID | COPERNICUS PMID 11386262 + PRADA Lancet 2018 PMID 26656872 — carvedilol may protect from anthracycline cardiotoxicity in active chemotherapy |
| sacubitril-valsartan | 24/26 BID titrate to 97/103 BID | PO | BID | PIONEER-HF PMID 30403955 + ACC/AHA 2022 HF — start once EF <40 + euvolemia + SBP ≥100 + ≥36h post-ACEi |
| methylprednisolone | 1–2 mg/kg/d IV | IV | daily × 3–5 d then PO prednisone taper | Mahmood NEJM 2018 PMID 30013321 + ASCO 2018 ICI cardiotoxicity guideline — high-dose corticosteroid first-line for ICI myocarditis; consider additional immunosuppression (mycophenolate, tacrolimus, infliximab) for refractory cases |
| verapamil | 80–120 mg PO TID | PO | TID | Discontinue offending fluoropyrimidine + use CCB to relieve coronary vasospasm in 5-FU/capecitabine cardiotoxicity |
| apixaban | 5 mg BID (or 2.5 mg per dose-reduction criteria) | PO | BID | Khorana NEJM 2019 — apixaban shown effective in cancer-associated thrombosis; use with caution + low-dose ASA (NOT triple therapy if avoidable) per ESC cardio-onc 2022 |
Plan: Active-cancer NSTEMI — high-bleeding-risk antithrombotic with shortened DAPT, conservative-vs-invasive shared decision, statin continued, BB per EF + chemo plan, ICI myocarditis steroids if indicated (ESC cardio-onc 2022 + ACC/AHA 2025 + MASTER DAPT)
Contact your care team if any of the following happen:
Call 911 or go to the nearest emergency room right away if you have:
Cardio-oncology clinic follow-up at 1 wk + 4 wk; oncology continuation decision re: chemotherapy hold/dose modification; cardiology long-term for any post-MI HF; mental health (cancer + cardiac dual-burden very high); palliative care if indicated; patient/family GOC re: future ICU + interventional escalation; primary care for medication reconciliation
Guideline: ESC 2022 Cardio-Oncology Guideline (PMID 36017575) + 2025 ACC/AHA ACS Guideline + ACC/AHA 2022 HF + ASCO 2018 ICI cardiotoxicity + MASTER DAPT